Takeaway 1: GSK is suing Pfizer over patent infringement for their respective respiratory syncytial virus (RSV) vaccines, Arexvy and Abrysvo. GSK claims that Pfizer's vaccine infringes on four of its patents.
Takeaway 2: Both GSK and Pfizer's vaccines target the RSV F protein, specifically the prefusion form which has been shown to elicit protective antibodies. Other companies, such as Moderna and Icosavax, are also developing RSV vaccines that address this conformation of the F protein.
Takeaway 3: GSK alleges that its RSV research dates back to the early 2000s, while Pfizer's research started in 2013, at least seven years later. GSK's complaint does not reference the National Institute for Allergy and Infectious Diseases (NIH) research that identified the prefusion form of the F protein.
Takeaway 2: Both GSK and Pfizer's vaccines target the RSV F protein, specifically the prefusion form which has been shown to elicit protective antibodies. Other companies, such as Moderna and Icosavax, are also developing RSV vaccines that address this conformation of the F protein.
Takeaway 3: GSK alleges that its RSV research dates back to the early 2000s, while Pfizer's research started in 2013, at least seven years later. GSK's complaint does not reference the National Institute for Allergy and Infectious Diseases (NIH) research that identified the prefusion form of the F protein.
[
add
]
[
|
|
...
]